Temat: "PROGRESSION-free survival" - OpacWWW

Skocz do pozycji: 1 1.

Tytuł :: A microfluidic cell-migration assay for the prediction of progression-free survival and recurrence time of patients with glioblastoma.
Autorzy :: Wong BS; Department of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, MD, USA.; Institute for NanoBioTechnology, Johns Hopkins University, Baltimore, MD, USA.
Shah SR; Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA.; Department of Neurosurgery, Mayo Clinic, Jacksonville, FL, USA.
Yankaskas CL; Department of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, MD, USA.; Institute for NanoBioTechnology, Johns Hopkins University, Baltimore, MD, USA.
Bajpai VK; Department of Chemical and Systems Biology, Stanford University, Stanford, CA, USA.; Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA, USA.
Wu PH; Department of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, MD, USA.; Institute for NanoBioTechnology, Johns Hopkins University, Baltimore, MD, USA.
Chin D; Department of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, MD, USA.
Ifemembi B; Department of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, MD, USA.; Institute for NanoBioTechnology, Johns Hopkins University, Baltimore, MD, USA.
ReFaey K; Department of Neurosurgery, Mayo Clinic, Jacksonville, FL, USA.
Schiapparelli P; Department of Neurosurgery, Mayo Clinic, Jacksonville, FL, USA.
Zheng X; Department of Embryology, Carnegie Institution for Science, Baltimore, MD, USA.
Martin SS; Marlene and Stewart Greenebaum National Cancer Institute Comprehensive Cancer Center, Department of Physiology, University of Maryland School of Medicine, Baltimore, MD, USA.
Fan CM; Department of Embryology, Carnegie Institution for Science, Baltimore, MD, USA.
Quiñones-Hinojosa A; Department of Neurosurgery, Mayo Clinic, Jacksonville, FL, USA. .
Konstantopoulos K; Department of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, MD, USA. .; Institute for NanoBioTechnology, Johns Hopkins University, Baltimore, MD, USA. .; Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA. .; Department of Oncology, Johns Hopkins University, Baltimore, MD, USA. .; Pokaż więcej
Źródło :: Nature biomedical engineering [Nat Biomed Eng] 2021 Jan; Vol. 5 (1), pp. 26-40. Date of Electronic Publication: 2020 Sep 28.
Typ publikacji :: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
MeSH Terms :: Brain Neoplasms*/diagnosis
Brain Neoplasms*/genetics
Brain Neoplasms*/metabolism
Brain Neoplasms*/mortality
Cell Movement*/genetics
Cell Movement*/physiology
Glioblastoma*/diagnosis
Glioblastoma*/genetics
Glioblastoma*/metabolism
Glioblastoma*/mortality
Microfluidic Analytical Techniques*/instrumentation
Microfluidic Analytical Techniques*/methods
Progression-Free Survival*
Adolescent ; Adult ; Aged ; Aged, 80 and over ; Cell Proliferation/genetics ; Cell Proliferation/physiology ; Gene Expression Regulation, Neoplastic/genetics ; Humans ; Middle Aged ; Prognosis ; RNA/analysis ; RNA/genetics ; RNA/metabolism ; Retrospective Studies ; Transcriptome/genetics ; Tumor Cells, Cultured ; Young Adult
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 2 2.

Tytuł :: Mitotic Index and Progression-Free Survival in Atypical Meningiomas.
Autorzy :: Domingo RA; Neurologic Surgery Department, Mayo Clinic, Jacksonville, Florida, USA.
Tripathi S; Neurologic Surgery Department, Mayo Clinic, Jacksonville, Florida, USA.
Vivas-Buitrago T; Neurologic Surgery Department, Mayo Clinic, Jacksonville, Florida, USA.
Lu VM; Neurologic Surgery Department, Mayo Clinic, Rochester, Minnesota, USA.
Chaichana KL; Neurologic Surgery Department, Mayo Clinic, Jacksonville, Florida, USA.
Quiñones-Hinojosa A; Neurologic Surgery Department, Mayo Clinic, Jacksonville, Florida, USA. Electronic address: .; Pokaż więcej
Źródło :: World neurosurgery [World Neurosurg] 2020 Oct; Vol. 142, pp. 191-196. Date of Electronic Publication: 2020 Jun 29.
Typ publikacji :: Journal Article; Review
MeSH Terms :: Progression-Free Survival*
Meningeal Neoplasms/*genetics
Meningioma/*genetics
Mitotic Index/*methods
Humans ; Meningeal Neoplasms/pathology ; Meningeal Neoplasms/surgery ; Meningioma/pathology ; Meningioma/surgery
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 3 3.

Tytuł :: Event-free survival at 24 months is a robust surrogate endpoint for long-term survival in pediatric, adolescent, and adult T cell lymphoblastic lymphoma.
Autorzy :: Chen H; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China.
Qin Y; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China.
Yang J; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China.
Liu P; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China.
Zhang C; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China.
He X; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China.
Zhou S; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China.
Yang S; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China.
Gui L; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China.
Zhou L; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China.
Sun Y; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China.
Shi Y; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China. .; Pokaż więcej
Źródło :: Annals of hematology [Ann Hematol] 2020 Dec; Vol. 99 (12), pp. 2847-2857. Date of Electronic Publication: 2020 Jul 25.
Typ publikacji :: Journal Article
MeSH Terms :: Progression-Free Survival*
Leukemia-Lymphoma, Adult T-Cell/*diagnostic imaging
Leukemia-Lymphoma, Adult T-Cell/*mortality
Adolescent ; Adult ; Biomarkers ; Child ; Child, Preschool ; Female ; Follow-Up Studies ; Humans ; Male ; Middle Aged ; Retrospective Studies ; Survival Rate/trends ; Time Factors ; Young Adult
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 4 4.

Tytuł :: Progression-free survival in the ICON8 trial - Authors' reply.
Autorzy :: James EC; Medical Research Council Clinical Trials Unit at University College London, Institute of Clinical Trials & Methodology, University College London, London WC1V 6LJ, UK. Electronic address: .
McNeish IA; Department of Surgery and Cancer, Imperial College London, London, UK.
Cook AD; Medical Research Council Clinical Trials Unit at University College London, Institute of Clinical Trials & Methodology, University College London, London WC1V 6LJ, UK.
Kaplan R; Medical Research Council Clinical Trials Unit at University College London, Institute of Clinical Trials & Methodology, University College London, London WC1V 6LJ, UK.
Clamp AR; Department of Medical Oncology, The Christie National Health Service Foundation Trust and University of Manchester, Manchester, UK.; Pokaż więcej
Źródło :: Lancet (London, England) [Lancet] 2020 Sep 12; Vol. 396 (10253), pp. 757.
Typ publikacji :: Letter; Comment
MeSH Terms :: Progression-Free Survival*
Disease-Free Survival
: Opinia redakcyjna

Szczegóły

Skocz do pozycji: 5 5.

Tytuł :: Progression-free survival in the ICON8 trial.
Autorzy :: Ludmir EB; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
McCaw ZR; Google, Mountain View, CA, USA.
Fuller CD; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Wei LJ; Department of Biostatistics, Harvard T H Chan School of Public Health, Boston, MA 02115, USA. Electronic address: .; Pokaż więcej
Źródło :: Lancet (London, England) [Lancet] 2020 Sep 12; Vol. 396 (10253), pp. 756.
Typ publikacji :: Letter; Comment
MeSH Terms :: Carcinoma*
Progression-Free Survival*
Antineoplastic Combined Chemotherapy Protocols ; Fallopian Tubes ; Female ; Humans
: Opinia redakcyjna

Szczegóły

Skocz do pozycji: 6 6.

Tytuł :: Progression-free survival in the ICON8 trial.
Autorzy :: Balieiro Anastacio da Costa AA; Department of Medical Oncology, A C Camargo Cancer Center, São Paulo 01525-001, Brazil. Electronic address: .
Baiocchi G; Department of Gynecologic Oncology, A C Camargo Cancer Center, São Paulo 01525-001, Brazil.
Guimarães APG; Department of Medical Oncology, A C Camargo Cancer Center, São Paulo 01525-001, Brazil.; Pokaż więcej
Źródło :: Lancet (London, England) [Lancet] 2020 Sep 12; Vol. 396 (10253), pp. 756-757.
Typ publikacji :: Letter; Comment
MeSH Terms :: Carcinoma*
Progression-Free Survival*
Antineoplastic Combined Chemotherapy Protocols ; Fallopian Tubes ; Female ; Humans
: Opinia redakcyjna

Szczegóły

Skocz do pozycji: 7 7.

Tytuł :: Long PFS of more than 7 years is achieved in 9% of myeloma patients in the era of conventional chemotherapy and of first-generation novel anti-myeloma agents: a single-center experience over 20-year period.
Autorzy :: Terpos E; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Alexandra General Hospital, 80 Vas. Sofias Avenue, 11528, Athens, Greece. .
Ntanasis-Stathopoulos I; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Alexandra General Hospital, 80 Vas. Sofias Avenue, 11528, Athens, Greece.
Roussou M; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Alexandra General Hospital, 80 Vas. Sofias Avenue, 11528, Athens, Greece.
Kanellias N; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Alexandra General Hospital, 80 Vas. Sofias Avenue, 11528, Athens, Greece.
Fotiou D; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Alexandra General Hospital, 80 Vas. Sofias Avenue, 11528, Athens, Greece.
Migkou M; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Alexandra General Hospital, 80 Vas. Sofias Avenue, 11528, Athens, Greece.
Eleutherakis-Papaiakovou E; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Alexandra General Hospital, 80 Vas. Sofias Avenue, 11528, Athens, Greece.
Gavriatopoulou M; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Alexandra General Hospital, 80 Vas. Sofias Avenue, 11528, Athens, Greece.
Kastritis E; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Alexandra General Hospital, 80 Vas. Sofias Avenue, 11528, Athens, Greece.
Dimopoulos MA; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Alexandra General Hospital, 80 Vas. Sofias Avenue, 11528, Athens, Greece.; Pokaż więcej
Źródło :: Annals of hematology [Ann Hematol] 2020 Jun; Vol. 99 (6), pp. 1257-1264. Date of Electronic Publication: 2020 May 07.
Typ publikacji :: Journal Article
MeSH Terms :: Progression-Free Survival*
Antineoplastic Agents/*therapeutic use
Multiple Myeloma/*diagnosis
Multiple Myeloma/*drug therapy
Adult ; Aged ; Aged, 80 and over ; Female ; Follow-Up Studies ; Humans ; Male ; Middle Aged ; Time Factors
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 8 8.

Tytuł :: Meta-analyses on progression-free survival as a surrogate endpoint for overall survival in triple-negative breast cancer.
Autorzy :: Hirai T; Teikyo University Graduate School of Public Health, 2-11-1 Kaga, Itabashi-ku, Tokyo, Japan.; Clinical Development Department, Daiichi Sankyo RD Novare Co., Ltd., Tokyo, Japan.
Nemoto A; Teikyo University Graduate School of Public Health, 2-11-1 Kaga, Itabashi-ku, Tokyo, Japan.
Ito Y; Breast Medical Oncology, Breast Oncology Center, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan.
Matsuura M; Teikyo University Graduate School of Public Health, 2-11-1 Kaga, Itabashi-ku, Tokyo, Japan. .; Division of Cancer Genomics, The Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan. .; Pokaż więcej
Źródło :: Breast cancer research and treatment [Breast Cancer Res Treat] 2020 May; Vol. 181 (1), pp. 189-198. Date of Electronic Publication: 2020 Apr 03.
Typ publikacji :: Journal Article; Meta-Analysis
MeSH Terms :: Biomarkers*
Progression-Free Survival*
Triple Negative Breast Neoplasms/*mortality
Triple Negative Breast Neoplasms/*pathology
Disease Progression ; Female ; Humans ; Survival Rate
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 9 9.

Tytuł :: A novel, more reliable approach to use of progression-free survival as a predictor of gain in overall survival: The Ottawa PFS Predictive Model.
Autorzy :: Stewart DJ; University of Ottawa and the Ottawa Hospital, 501 Smyth Road, Ottawa, ON, K1H 8L6, Canada. Electronic address: .
Bossé D; University of Ottawa and the Ottawa Hospital, 501 Smyth Road, Ottawa, ON, K1H 8L6, Canada. Electronic address: .
Goss G; University of Ottawa and the Ottawa Hospital, 501 Smyth Road, Ottawa, ON, K1H 8L6, Canada. Electronic address: .
Hilton JF; University of Ottawa and the Ottawa Hospital, 501 Smyth Road, Ottawa, ON, K1H 8L6, Canada. Electronic address: .
Jonker D; University of Ottawa and the Ottawa Hospital, 501 Smyth Road, Ottawa, ON, K1H 8L6, Canada. Electronic address: .
Fung-Kee-Fung M; University of Ottawa and the Ottawa Hospital, 501 Smyth Road, Ottawa, ON, K1H 8L6, Canada. Electronic address: .; Pokaż więcej
Źródło :: Critical reviews in oncology/hematology [Crit Rev Oncol Hematol] 2020 Apr; Vol. 148, pp. 102896. Date of Electronic Publication: 2020 Feb 08.
Typ publikacji :: Journal Article; Review
MeSH Terms :: Disease-Free Survival*
Progression-Free Survival*
Randomized Controlled Trials as Topic*
Antineoplastic Agents/*therapeutic use
Neoplasms/*mortality
Disease Progression ; Humans ; Medical Oncology ; Neoplasm Recurrence, Local/mortality ; Neoplasms/drug therapy ; Neoplasms/pathology ; Proportional Hazards Models ; Survival Analysis
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 10 10.

Tytuł :: Microvascular Impairment After Myocardial Infarction: It Is Not Just About Obstruction.
Autorzy :: Lindner JR; Knight Cardiovascular Institute, the Oregon National Primate Research Center, Oregon Health and Science University, Portland.; Pokaż więcej
Źródło :: Circulation. Cardiovascular imaging [Circ Cardiovasc Imaging] 2020 Jun; Vol. 13 (6), pp. e011083. Date of Electronic Publication: 2020 Jun 12.
Typ publikacji :: Editorial; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Comment
MeSH Terms :: Myocardial Infarction*/diagnostic imaging
Progression-Free Survival*
Coronary Circulation ; Humans
: Raport

Szczegóły

Skocz do pozycji: 11 11.

Tytuł :: Informative censoring - a neglected cause of bias in oncology trials.
Autorzy :: Templeton AJ; Department of Oncology, St. Claraspital Basel, University of Basel, Basel, Switzerland.; Faculty of Medicine, University of Basel, Basel, Switzerland.
Amir E; Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada.
Tannock IF; Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada. .; Pokaż więcej
Źródło :: Nature reviews. Clinical oncology [Nat Rev Clin Oncol] 2020 Jun; Vol. 17 (6), pp. 327-328.
Typ publikacji :: Journal Article
MeSH Terms :: Bias*
Progression-Free Survival*
Survival Rate*
Neoplasms/*therapy
Humans ; Intention to Treat Analysis ; Randomized Controlled Trials as Topic
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 12 12.

Tytuł :: Dual HER2 blockade in the first-line treatment of metastatic breast cancer - A retrospective population-based observational study in Danish patients.
Autorzy :: Christensen T; Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Blegdamsvej 9, 2100, Copenhagen, Denmark. Electronic address: .
Berg T; Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Blegdamsvej 9, 2100, Copenhagen, Denmark.
Nielsen LB; Danish Breast Cancer Group, Rigshospitalet, Copenhagen University Hospital, Standboulevarden 49, 2100, Copengahen, Denmark.
Andersson M; Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Blegdamsvej 9, 2100, Copenhagen, Denmark.
Jensen MB; Danish Breast Cancer Group, Rigshospitalet, Copenhagen University Hospital, Standboulevarden 49, 2100, Copengahen, Denmark.
Knoop A; Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Blegdamsvej 9, 2100, Copenhagen, Denmark.; Pokaż więcej
Źródło :: Breast (Edinburgh, Scotland) [Breast] 2020 Jun; Vol. 51, pp. 34-39. Date of Electronic Publication: 2020 Mar 13.
Typ publikacji :: Journal Article; Observational Study
MeSH Terms :: Progression-Free Survival*
Antibodies, Monoclonal, Humanized/*therapeutic use
Antineoplastic Agents, Immunological/*therapeutic use
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Breast Neoplasms/*drug therapy
Trastuzumab/*therapeutic use
Aged ; Aged, 80 and over ; Databases, Factual ; Denmark/epidemiology ; Female ; Humans ; Middle Aged ; Randomized Controlled Trials as Topic ; Receptor, ErbB-2/antagonists & inhibitors ; Retrospective Studies
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 13 13.

Tytuł :: Objective Response and Prolonged Disease Control of Advanced Adrenocortical Carcinoma with Cabozantinib.
Autorzy :: Kroiss M; Dept. of Internal Medicine I, Division of Endocrinology and Diabetes, University Hospital Würzburg, University of Würzburg, Germany.; Comprehensive Cancer Center Mainfranken, University of Würzburg, Germany.; Core Unit Clinical Mass Spectrometry, University Hospital Würzburg, University of Würzburg, Germany.
Megerle F; Dept. of Internal Medicine I, Division of Endocrinology and Diabetes, University Hospital Würzburg, University of Würzburg, Germany.
Kurlbaum M; Dept. of Internal Medicine I, Division of Endocrinology and Diabetes, University Hospital Würzburg, University of Würzburg, Germany.; Core Unit Clinical Mass Spectrometry, University Hospital Würzburg, University of Würzburg, Germany.
Zimmermann S; Core Unit Clinical Mass Spectrometry, University Hospital Würzburg, University of Würzburg, Germany.; Institute for Pharmacy and Food Chemistry, University of Würzburg, Germany.
Wendler J; Dept. of Internal Medicine I, Division of Endocrinology and Diabetes, University Hospital Würzburg, University of Würzburg, Germany.
Jimenez C; The University of Texas MD Anderson Cancer Center, Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, Houston, Texas, USA.
Lapa C; Department of Nuclear Medicine, University Hospital Würzburg, University of Würzburg, Germany.
Quinkler M; Charité University Medicine and Endokrinologie in Charlottenburg, Berlin, Germany.
Scherf-Clavel O; Institute for Pharmacy and Food Chemistry, University of Würzburg, Germany.
Habra MA; The University of Texas MD Anderson Cancer Center, Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, Houston, Texas, USA.
Fassnacht M; Dept. of Internal Medicine I, Division of Endocrinology and Diabetes, University Hospital Würzburg, University of Würzburg, Germany.; Comprehensive Cancer Center Mainfranken, University of Würzburg, Germany.; Pokaż więcej
Źródło :: The Journal of clinical endocrinology and metabolism [J Clin Endocrinol Metab] 2020 May 01; Vol. 105 (5).
Typ publikacji :: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :: Progression-Free Survival*
Adrenal Cortex Neoplasms/*drug therapy
Adrenocortical Carcinoma/*drug therapy
Anilides/*therapeutic use
Pyridines/*therapeutic use
Adrenal Cortex Neoplasms/epidemiology ; Adrenal Cortex Neoplasms/pathology ; Adrenocortical Carcinoma/epidemiology ; Adrenocortical Carcinoma/pathology ; Adult ; Aged ; Cohort Studies ; Disease Progression ; Female ; Germany/epidemiology ; Humans ; Male ; Middle Aged ; Neoplasm Staging ; Registries ; Retrospective Studies ; Salvage Therapy ; Treatment Outcome ; United States/epidemiology ; Young Adult
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 14 14.

Tytuł :: ASO Author Reflections: Effect of Primary Surgery on Quality of Life in De Novo Stage IV Breast Cancer Patients.
Autorzy :: Si Y; National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Yuan P; National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. .; Pokaż więcej
Źródło :: Annals of surgical oncology [Ann Surg Oncol] 2020 Apr; Vol. 27 (4), pp. 1034-1035. Date of Electronic Publication: 2020 Feb 07.
Typ publikacji :: Journal Article
MeSH Terms :: Progression-Free Survival*
Quality of Life*
Breast Neoplasms/*surgery
Mastectomy/*methods
Breast Neoplasms/epidemiology ; Breast Neoplasms/pathology ; China/epidemiology ; Female ; Humans ; Neoplasm Recurrence, Local ; Neoplasm Staging ; Prognosis ; Retrospective Studies
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 15 15.

Tytuł :: Multidisciplinary tumor boards and their analyses: the yin and yang of outcome measures.
Autorzy :: Engelhardt, Monika (AUTHOR)
Ihorst, Gabriele (AUTHOR)
Schumacher, Martin (AUTHOR)
Rassner, Michael (AUTHOR)
Gengenbach, Laura (AUTHOR)
Möller, Mandy (AUTHOR)
Shoumariyeh, Khalid (AUTHOR)
Neubauer, Jakob (AUTHOR)
Farthmann, Juliane (AUTHOR)
Herget, Georg (AUTHOR)
Wäsch, Ralph (AUTHOR); Pokaż więcej
Źródło :: BMC Cancer. 2/17/2021, Vol. 21 Issue 1, p1-4. 4p.
: Czasopismo naukowe

Szczegóły Pełny tekst Pełny tekst

Skocz do pozycji: 16 16.

Tytuł :: Adjuvant radiotherapy versus observation following gross total resection for atypical meningioma: a systematic review and meta-analysis.
Autorzy :: Chun, Se-Woong (AUTHOR)
Kim, Kyung Min (AUTHOR)
Kim, Min-Sung (AUTHOR)
Kang, Ho (AUTHOR)
Dho, Yun-Sik (AUTHOR)
Seo, Youngbeom (AUTHOR)
Kim, Jin Wook (AUTHOR)
Kim, Yong Hwy (AUTHOR)
Park, Chul-Kee (AUTHOR); Pokaż więcej
Źródło :: Radiation Oncology. 2/17/2021, Vol. 16 Issue 1, p1-14. 14p.
: Czasopismo naukowe

Szczegóły Pełny tekst Pełny tekst

Skocz do pozycji: 17 17.

Tytuł :: Vasculogenic mimicry, a negative indicator for progression free survival of lung adenocarcinoma irrespective of first line treatment and epithelial growth factor receptor mutation status.
Autorzy :: He, Xuejun (AUTHOR)
You, Jijun (AUTHOR)
Ding, Haibing (AUTHOR)
Zhang, Zhisheng (AUTHOR)
Cui, Lin (AUTHOR)
Shen, Xiaomei (AUTHOR)
Bian, Xiaoxia (AUTHOR)
Liu, Yanqing (AUTHOR)
Chen, Jue (AUTHOR); Pokaż więcej
Źródło :: BMC Cancer. 2/6/2021, Vol. 21 Issue 1, p1-9. 9p.
: Czasopismo naukowe

Szczegóły Pełny tekst Pełny tekst

Skocz do pozycji: 18 18.

Tytuł :: Impact of Postmastectomy Radiotherapy on Locoregional Control and Disease-Free Survival in Patients with Breast Cancer Treated with Neoadjuvant Chemotherapy.
Autorzy :: Zhang, Yanyu (AUTHOR)
Zhang, Yaotian (AUTHOR)
Liu, Zhuang (AUTHOR)
Qin, Zilan (AUTHOR)
Li, Yubing (AUTHOR)
Zhao, Jiaming (AUTHOR)
Ma, Xinchi (AUTHOR)
Yang, Qiankun (AUTHOR)
Han, Ning (AUTHOR)
Zeng, Xue (AUTHOR)
Guo, Hong (AUTHOR)
Zhang, Na (AUTHOR); Pokaż więcej
Źródło :: Journal of Oncology. 1/25/2021, p1-11. 11p.
: Czasopismo naukowe

Szczegóły Pełny tekst Pełny tekst

Skocz do pozycji: 19 19.

Tytuł :: Low GSTM3 expression is associated with poor disease‐free survival in resected esophageal squamous cell carcinoma.
Autorzy :: Yang, Fu (AUTHOR)
Wen, Jing (AUTHOR)
Luo, Kongjia (AUTHOR)
Fu, Jianhua (AUTHOR); Pokaż więcej
Źródło :: Diagnostic Pathology. 1/22/2021, Vol. 16 Issue 1, p1-12. 12p.
: Czasopismo naukowe

Szczegóły Pełny tekst Pełny tekst

Skocz do pozycji: 20 20.

Tytuł :: CAMK2N1/RUNX3 methylation is an independent prognostic biomarker for progression-free and overall survival of platinum-sensitive epithelial ovarian cancer patients.
Autorzy :: Heinze, Karolin (AUTHOR)
Rengsberger, Matthias (AUTHOR)
Gajda, Mieczyslaw (AUTHOR)
Jansen, Lars (AUTHOR)
Osmers, Linea (AUTHOR)
Oliveira-Ferrer, Leticia (AUTHOR)
Schmalfeldt, Barbara (AUTHOR)
Dürst, Matthias (AUTHOR)
Häfner, Norman (AUTHOR)
Runnebaum, Ingo B. (AUTHOR); Pokaż więcej
Źródło :: Clinical Epigenetics. 1/22/2021, Vol. 13 Issue 1, p1-13. 13p.
: Czasopismo naukowe

Szczegóły Pełny tekst Pełny tekst

Informacja

Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""PROGRESSION-free survival"" wg kryterium: Temat

Źródło danych

Ogranicz do:

Ogranicz do bazy

Typ dokumentu

Temat

Wydawca

Publikacja

Język